This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer’s Disease. Neurobiol Aging 1998;19:109–116
Kantarci K, Clifford RJ. Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease. NeuroRx 2004;1:196–205
Jagust W. Molecular neuroimaging in Alzheimer’s disease. NeuroRx 2004;1:206–212
Brooks DJ. Neuroimaging in Parkinson’s disease NeuroRx 2004;1:243–254
Selkoe DJ. Alzheimer’s disease: genotypes, phenotypes and treatments. Science 1997;271:630–631
Spillantini MG, Schmidt MI, Lee MY, et al. α-Synuclein in Lewy bodies. Nature 1997;388:839–840
Irizarry M, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998;57:334–337
Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;4:601–607
Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 2004;1:213–225
Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 1996;2:864–870
Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1–42 and incipient Alzheimer’s disease. Ann Neurol 1999;46:412–416
Fukumoto H, Tennis M, Locascio J, et al. Age but not diagnosis is the main predictor of plasma amyloid β-protein levels. Arch Neurol 2003;60:958–964
O’Suilleabhain PE, Bottiglieri T, Dewey RB, et al. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson’s disease. Mov Disord 2004;19:1403–1408.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this paper
Cite this paper
Growdon, J.H., Irizarry, M.C., Scherzer, C. (2008). Biomarkers for Alzheimer’s Disease and Parkinson’s Disease. In: Fisher, A., Memo, M., Stocchi, F., Hanin, I. (eds) Advances in Alzheimer’s and Parkinson’s Disease. Advances in Behavioral Biology, vol 57. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-72076-0_16
Download citation
DOI: https://doi.org/10.1007/978-0-387-72076-0_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-72074-6
Online ISBN: 978-0-387-72076-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)